This study evaluated the efficacy and safety of barnidipine for the treatment of mild-to-moderate essential hypertension in Chinese patients. A total of 131 patients were randomized to receive either barnidipine (10-15 mg) or felodipine (5-10 mg) once daily for 4 weeks. Both drugs reduced blood pressure significantly, with ≥ 87% of patients obtaining a marked or moderate effect. The mean ± SD reductions in systolic and diastolic blood pressure were 19.2 ± 13.6 and 14.4 ± 7.0 mmHg, respectively, for barnidipine treatment, and 20.3 ± 11.3 and 14.7 ± 7.7 mmHg, respectively, for felodipine treatment. There were no significant differences between the two drugs in terms of anti-hypertensive effect, heart rate, laboratory test results or incidence of adverse events. More patients taking felodipine experienced palpitations, but this difference was not statistically significant. Barnidipine is as efficacious and safe as felodipine in the treatment of essential hypertension in Chinese patients.
BurtVLWheltonPRoccellaEJBrownCCutlerJAHigginsM: Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension1995; 25: 305–313.
2.
Joint National Committee: The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med1997; 157: 2413–2446.
3.
EisenSAMillerDKWoodwardRSSpitznagelEPrzybeckTR: The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med1990; 150: 1881–1884.
4.
HashimotoKMotomuraSTsujimotoGHiguchiSTeramuraT: Phase I study of a calcium antagonist, YM730 (mepirodipine hydrochloride) (in Japanese). Kiso to Rinsho1990; 24: 4443–4458.
5.
SarutaTSuzukiH: Single dose study of barnidipine hydrochloride (YM730) in essential hypertension. J Med Pharm Sci1992; 28: 178–185.
6.
KorstanjeC: Barnidipine, a long-acting slow onset calcium antagonist. Int J Clin Pract Suppl2000; 114: 2–5.
7.
SuzukiSMatsuokaHTodaG: Effect of long-term administration of mepirodipine hydrochloride (YM730), a long-acting calcium antagonist, on blood pressure, serum lipids and carbohydrate metabolism in patients with essential hypertension (in Japanese). Rinsho to Kenkyu1990; 67: 3589–3596.
8.
ImaiYAbeKNishiyamaASekinoMYoshinagaK: Evaluation of the antihypertensive effect of barnidipine, a dihydropyridine calcium entry blocker, as determined by the ambulatory blood pressure level averaged for 24 h, daytime, and nighttime. Barnidipine Study Group. Am J Hypertens1997; 10: 1415–1419.
9.
BaeJHLeeJJKwonSHKangHSChoueCWKimKS: An open-label, uncontrolled, 8-week clinical trial of barnidipine hydrochloride, a once-daily calcium channel blocker, in Korean patients with essential hypertension. Curr Ther Res1997; 58: 382–389.
10.
ArgenzianoLIzzoRIovinoGDe LucaNParrellaLMoriscoC: Distinct vasodilation, without reflex neurohormonal activation, induced by barnidipine in hypertensive patients. Blood Press Suppl1998; 1: 9–14.
11.
SpiekerC: Efficacy and tolerability of once-daily barnidipine in the clinical management of patients with mild to moderate essential hypertension. Blood Press Suppl1998; 1: 15–21.
12.
van der VeldenJBeudekerHJNishiM: Diversity and intensity of adverse events in the treatment of hypertension with barnidipine. Blood Press Suppl1998; 1: 27–29.
13.
OtterstadJERuilopeLM: Treatment of hypertension in the very old. Int J Clin Pract Suppl2000; 114: 10–19.
14.
SmildeJG: The long-term efficacy and safety profile of barnidipine. Int J Clin Pract Suppl2000; 114: 20–26.
15.
NaberFBHageRMortelmansJ: Barnidipine monotherapy and combination therapy in older patients with essential hypertension: A long-term study. Int J Clin Pract Suppl2000; 114: 27–35.
16.
Guidelines Subcommittee: 1999 World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens1999; 17: 151–183.
17.
KirkendallWMBurtonACEpsteinFMFreisED: Recommendations for human blood pressure determination by sphygmomanometers. Circulation1967; 36: 980–988.
18.
HoriuchiIMatsuuraHHayashiKOkamotoMInoueIMizunoT: Antihypertensive effect on serum lipid of mepirodipine hydrochloride (YM730) in patients with essential hypertension (in Japanese). Shinryo to Shinyaku1990; 27: 1135–1145.
19.
KuriharaHNakajimaHHamaguchiTMiyagawaJNanbaMHanabusaT: Effect of barnidipine hydrochloride (Hypoca) on uric acid metabolism in patients with diabetes (in Japanese). Shinryo to Shinyaku1998; 35: 61–64.
20.
LiauCSChienKLChaoCLLeeTM: Efficacy and safety of barnidipine compared with felodipine in the treatment of hypertension in Chinese patients. J Int Med Res2002; 30: 330–336.
21.
TeramuraTFukunagaYvan HoogdalemEJWatanabeTHiguchiS: Examination of metabolic pathways and identification of human liver cytochrome P450 isozymes responsible for the metabolism of barnidipine, a calcium channel blocker. Xenobiotica1997; 27: 885–900.
22.
TeramuraTWatanabeTHiguchiSHashimotoK: Metabolism and pharmacokinetics of barnidipine hydrochloride, a calcium channel blocker, in man following oral administration of its sustained release formulation. Xenobiotica1997; 27: 203–216.
23.
SakaiTTeramuraTOkamiyaHInagakiO: A review on barnidipine: A novel calcium antagonist. Cardiovascular Drug Reviews1997; 15: 273–290.
24.
YoshinagaKIimuraKAbeKIshiiASarutaKTakedaK: Clinical study of calcium antagonist mepirodipine hydrochloride in renal hypertension (in Japanese). Jpn Pharmacol Ther1990; 18: 165–178.
25.
YuasaSShojiTSumikuraTTakahashiNUchidaKFujitaY: Effects of barnidipine hydrochloride on blood pressure and renal function in patients with renal hypertension (in Japanese). Prog Med1995; 15: 2378–2382.
26.
ParkHCKwonKHNohHJLeeIHKangSWChoiKH: Open-label, uncontrolled, clinical trial of barnidipine hydrochloride in Korean patients with renal parenchymal hypertension. Curr Ther Res2000; 61: 927–937.
27.
ChenXZhengFChenPTangLWeiRYuY: An open-label, randomized, controlled, 4-week comparitive clinical trial of barnidipine hydrochoride, a calcium-channel blocker, and benazepril, an angiotensin-converting enzyme inhibitor, in Chinese patients with renal parenchymal hypertension. J Int Med Res2006; 34: 121–128.
